# Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

> **NCT00661427** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 61 (actual)

## Conditions studied

- Head and Neck
- Squamous Cell Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **BIOLOGICAL:** cetuximab

## Key facts

- **NCT ID:** NCT00661427
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2018-01-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661427, "Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00661427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*